Loading clinical trials...
Loading clinical trials...
This is an observational study related to a medical device designed for the prevention of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with gastrointestinal cancer. The primary objecti...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Corporacion Parc Tauli
NCT07423390 · Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, Chemotherapy-induced
NCT06736600 · Peripheral Neuropathy Due to Chemotherapy
NCT07403071 · Multiple Myeloma, Peripheral Neuropathy Due to Chemotherapy
NCT07203066 · Peripheral Neuropathy Due to Chemotherapy, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, and more
NCT07095998 · Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, and more
Consorci Corporació Sanitària Parc Taulí
Sabadell, Barcelona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions